Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ImClone Systems
ImClone and Merck amend and supplement Erbitux agreement
August 18th, 2006
ImClone Systems, Inc., (IMCL) and Merck, KGaA, Darmstadt, Germany, announced that they have entered into agreements amending and supplementing the 1998 development and license agreement covering Erbitux and certain other work in the field of epidermal growth factor receptor (EGFR)-targeted antibodies. As part of the agreements, ImClone Systems consented to Merck's sublicense of certain intellectual property rights relating to the development and commercialization of an anti-EGFR antibody to Takeda Pharmaceutical Co. Merck and Takeda signed an alliance in September 2005 for the development and commercialization of matuzumab (EMD72000), a humanized EGFR-targeting...
Source: Biotech Law Weekly (2006-08-18)
|
